BLCO Bausch + Lomb Corp.
- 14.010
- +0.150+1.08%
Bausch + Lomb Corp. News
Bausch + Lomb Corp. Is Maintained at In-Line by Evercore Partners
Bausch + Lomb Corp. Is Maintained at In-Line by Evercore Partners
Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating
Bausch + Lomb (BLCO) has an average rating of outperform and price targets ranging from $14 to $26, according to analysts polled by Capital IQ. Price: 13.43, Change: -0.31, Percent Change: -2.28
HC Wainwright & Co. Reiterates Buy on Bausch & Lomb, Maintains $20 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and maintains $20 price target.
Earnings Call Summary | Bausch + Lomb Corp.(BLCO.US) Q1 2024 Earnings Conference
The following is a summary of the Bausch + Lomb Corporation (BLCO) Q1 2024 Earnings Call Transcript:Financial Performance:Bausch + Lomb reported Q1 revenue of $1.099 billion, up 20% in constant curren
Needham Reiterates Hold on Bausch & Lomb
Needham analyst David Saxon reiterates Bausch & Lomb with a Hold.
Bausch & Lomb Corp (BLCO) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Net Loss Widening
Bausch + Lomb Quarterly Loss Widens
By Robb M. Stewart Bausch + Lomb's loss in the first quarter widened with a rise in interest expenses and provisions for taxes, offsetting increased product sales. The Canadian eye-health company re
Bausch + Lomb Raises Full-Year 2024 Constant Currency Revenue Growth Guidance From 12-14% To 13-15%, With Revenue Guidance Of $4.6B–$4.7B Versus Consensus Of $4.66B
Bausch + Lomb Raises Full-Year 2024 Constant Currency Revenue Growth Guidance From 12-14% To 13-15%, With Revenue Guidance Of $4.6B–$4.7B Versus Consensus Of $4.66B
Bausch & Lomb Q1 2024 Adj EPS $0.07 Beats $0.05 Estimate, Sales $1.099B Beat $1.065B Estimate
Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05 by 40 percent. This is a 30 percent decrease over earnings of $0.10 per shar
Press Release: Bausch + Lomb Announces First-Quarter 2024 Results
Bausch + Lomb Announces First-Quarter 2024 Results -- Revenue of $1.099 Billion -- GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million -- Adjusted EBITDA (non-GA
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
21 Poster Presentations include Evaluations of Consumer, Pharmaceutical, Surgical and Vision Care Products and Pipeline Programs, Including a Novel Dry Eye Nutritional Supplement Bausch + Lomb Corporation (TSX:BLCO),
Are Investors Undervaluing Bausch + Lomb Corporation (NYSE:BLCO) By 33%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Bausch + Lomb fair value estimate is US$22.22 Current share price of US$14.79 suggests Bausch + Lomb is potentially 33% undervalued The US
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
Novel Supplement Shown to Address Signs and Symptoms of Dry Eyes, All Primary Endpoints Achieved Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live
Royal Bank of Canada: Maintaining the Bausch & Lomb (BLCO.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $20.00 to $18.00.
Royal Bank of Canada: Maintaining the Bausch & Lomb (BLCO.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $20.00 to $18.00.
RBC Capital Maintains Outperform on Bausch & Lomb, Lowers Price Target to $18
RBC Capital analyst Douglas Miehm maintains Bausch & Lomb (NYSE:BLCO) with a Outperform and lowers the price target from $20 to $18.
Bausch + Lomb Q1 Results Likely to Be Impacted by Foreign Exchange Headwinds, RBC Says
Bausch + Lomb's (BLCO) Q1 financial results are expected to be affected by continued foreign exchange headwinds, RBC Capital Markets said Monday. The eye health company is scheduled to report Q1 resul
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue Eye Care Recycling programs have
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch +
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says
Bausch Health (BHC) received a "positive" appellate court ruling on Xifaxan, though the market is assigning only a 32% chance of Bausch + Lomb (BLCO) distribution, RBC Capital Markets said Friday in a
Unusual Options Activity: SBUX, ROIV and Others Attract Market Bets, SBUX V/OI Ratio Reaches 111.0
EST Apr 5th Closing Delivery - In the last three hours of trading, 6 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Analysis
Price Target
No Data
